ORLANDO, FL USA (UroToday.com) - Dr. Malte Rieken presented predictors of cancer-specific mortality (CSM) from recurrent penile squamous cell carcinoma after primary surgical therapy. He reviewed retrospective data on 314 patients who had a recurrence over the course of 63 years. Thirty percent underwent inguinal lymphadenectomy and 41% of the patients had adjuvant radiation. Most patients with recurrence had a local recurrence, and 10% had distal metastasis. auaThere as a 10.5 month median time to recurrence in this cohort, and on regression analysis, shorter time to recurrence, regional and distal recurrence, and nodal status were predictors of poor outcome.

Overall, this data might be used to risk stratify patients at the time of recurrence to help guide decisions regarding further therapy in the context of patient comorbidities.

Presented by Malte Rieken at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

New York, NY USA

Written by Phillip Abbosh, MD, PhD, medical writer for UroToday.com


Upcoming urology industry events
April 27-29, 2018 / European Society for Medical Oncology Update for Practising Oncologists
European Society for Medical Oncology Update for Practising Oncologists
May 14, 2018 / InterContinental Mark Hopkins Hotel
SITC Cancer Immune Responsiveness Workshop
May 16-17, 2018 / InterContinental Mark Hopkins Hotel
SITC Immuno-Oncology Biomarkers: State of the Art Workshop
May 17, 2018 / Moscone Convention Center North/South, San Francisco, CA
SAU 2018 Annual Meeting at the AUA
Print publications focusing on urological cancer treatments through original commentary & articles

Everyday Urology™ - Oncology Insights

From the Editor

Prostate Cancer and Prostatic Diseases

From the Editor